Last reviewed · How we verify
Tritanrix-HepB/Hib-MenAC
Tritanrix-HepB/Hib-MenAC is a vaccine that protects against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases.
Tritanrix-HepB/Hib-MenAC is a vaccine that protects against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases. Used for Protection against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases.
At a glance
| Generic name | Tritanrix-HepB/Hib-MenAC |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the body's immune system to produce antibodies against these pathogens, providing immunity against future infections.
Approved indications
- Protection against diphtheria, tetanus, hepatitis B, and meningococcal and Haemophilus influenzae type b diseases
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study (PHASE3)
- Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants (PHASE3)
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth (PHASE3)
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix-HepB/Hib-MenAC CI brief — competitive landscape report
- Tritanrix-HepB/Hib-MenAC updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI